title: Intrathecal 131I-labeled antitenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: phase I trial results.
abstract: We aimed to determine the maximum tolerated dose (MTD) of 131I-labeled 81C6 in patients with leptomeningeal neoplasms or brain tumor resection cavities with subarachnoid communication and to identify any objective responses. 81C6 is a murine IgG monoclonal antibody that reacts with tenascin in gliomas/carcinomas but does not react with normal adult brain. 131I-labeled 81C6 delivers intrathecal (IT) radiation to these neoplasms. This study was a Phase I trial in which patients were treated with a single IT dose of 131I-labeled 81C6. Cohorts of three to six patients were treated with escalating doses of 131I (starting dose, 40 mCi; 20 mCi escalations) on 10 mg 81C6. MTD is defined as the highest dose resulting in serious toxicity in no more than two of six patients. Serious toxicity is defined as grade III/IV nonhematological toxicity or major hematological toxicity. We treated 31 patients (8 pediatric and 23 adult). Eighteen had glioblastoma multiforme. Patients were treated with 131I doses from 40 to 100 mCi. Hematological toxicity was dose limiting and correlated with the administered 131I dose. No grade III/IV nonhematological toxicities were encountered. A partial response occurred in 1 patient and disease stabilization occurred in 13 (42%) of 31 patients. Twelve patients are alive (median follow-up, > 320 days); five are progression free >409 days median posttreatment. The MTD of a single IT administration of 131I-labeled 81C6 in adults is 80 mCi 131I-labeled 81C6. The MTD in pediatric patients was not reached at 131I doses up to 40 mCi normalized for body surface area.
authors.affiliation: Duke University Medical Center, Durham, North Carolina 27710, USA.
authors.forename: M T
authors.initials: MT
authors.lastname: Brown
authors.forename: R E
authors.initials: RE
authors.lastname: Coleman
authors.forename: A H
authors.initials: AH
authors.lastname: Friedman
authors.forename: H S
authors.initials: HS
authors.lastname: Friedman
authors.forename: R E
authors.initials: RE
authors.lastname: McLendon
authors.forename: R
authors.initials: R
authors.lastname: Reiman
authors.forename: G J
authors.initials: GJ
authors.lastname: Felsberg
authors.forename: R D
authors.initials: RD
authors.lastname: Tien
authors.forename: S H
authors.initials: SH
authors.lastname: Bigner
authors.forename: M R
authors.initials: MR
authors.lastname: Zalutsky
authors.forename: X G
authors.initials: XG
authors.lastname: Zhao
authors.forename: C J
authors.initials: CJ
authors.lastname: Wikstrand
authors.forename: C N
authors.initials: CN
authors.lastname: Pegram
authors.forename: J E
authors.initials: JE
authors.lastname: Herndon
authors.forename: N A
authors.initials: NA
authors.lastname: Vick
authors.forename: N
authors.initials: N
authors.lastname: Paleologos
authors.forename: R K
authors.initials: RK
authors.lastname: Fredericks
authors.forename: S C
authors.initials: SC
authors.lastname: Schold
authors.forename: D D
authors.initials: DD
authors.lastname: Bigner
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000401:mortality / Q000532:radiotherapy*; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use*; D008297:Male; D008577:Meningeal Neoplasms / Q000401:mortality / Q000532:radiotherapy*; D051379:Mice; D008875:Middle Aged; D016499:Radioimmunotherapy / Q000009:adverse effects; D011879:Radiotherapy Dosage
chemical_list: D000911:Antibodies, Monoclonal; D007457:Iodine Radioisotopes